Effect of auranofin on antibody-dependent cellular cytotoxicity (ADCC) mediated by rat peripheral blood polymorphonuclear leukocytes and mononuclear cells
- PMID: 6776048
- DOI: 10.1007/BF00915029
Effect of auranofin on antibody-dependent cellular cytotoxicity (ADCC) mediated by rat peripheral blood polymorphonuclear leukocytes and mononuclear cells
Abstract
Auranofin and other clinically used gold compounds were evaluated in vitro for effects on antibody-dependent cellular cytotoxicity (ADCC) of L929 fibroblast target cells mediated by adjuvant rat peripheral blood PMNs or mononuclear cells. Auranofin (10 microM) was found to be a potent inhibitor of PMNADCC. In contrast, gold sodium thiomalate (10-100 microM), gold thioglucose (10-1000 microM), and nongold substructures of auranofin (10 microM) were not inhibitory.. In continuous culture, gold sodium thiomalate and relatively low concentrations of auranofin (smaller than or equal to microM) significantly enhanced PMNADCC. Results of pretreatment studies indicate that auranofin's inhibitory activity of PMNADCC is caused by a noncytotoxic effect on PMN function which is not associated with alteration of PMN-target cell contact. In contrast to its inhibitory activity on PMNADCC, auranofin pretreatment of mononuclear cells resulted in enhanced target cell destruction which appeared to correlate with increased mononuclear cell-target cell contact.
Similar articles
-
Mechanisms of action of auranofin: effects on humoral immune response.J Rheumatol Suppl. 1982 Jul-Aug;8:32-6. J Rheumatol Suppl. 1982. PMID: 6813489
-
Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. A new chrysotherapeutic agent.Inflammation. 1977 Jun;2(2):131-42. doi: 10.1007/BF00918675. Inflammation. 1977. PMID: 104927
-
Immunopharmacology of auranofin and gold sodium thiomalate: effects on humoral immunity.J Rheumatol Suppl. 1979;5:74-81. J Rheumatol Suppl. 1979. PMID: 114651
-
Biologic actions and pharmacokinetic studies of auranofin.Am J Med. 1983 Dec 30;75(6A):90-108. doi: 10.1016/0002-9343(83)90481-3. Am J Med. 1983. PMID: 6318557 Review.
-
The pharmacological profile of auranofin, an orally active gold compound.Scand J Rheumatol Suppl. 1983;51:16-25. doi: 10.3109/03009748309095339. Scand J Rheumatol Suppl. 1983. PMID: 6426049 Review.
Cited by
-
Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.Drugs. 1984 May;27(5):378-424. doi: 10.2165/00003495-198427050-00002. Drugs. 1984. PMID: 6426923 Review.
-
Auranofin inhibits calcium uptake into opsonized-zymosan-stimulated neutrophils obtained from rats.Inflamm Res. 1995 Nov;44(11):482-5. doi: 10.1007/BF01837914. Inflamm Res. 1995. PMID: 8597882
-
Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin.Clin Rheumatol. 1984 Mar;3 Suppl 1:25-32. doi: 10.1007/BF03342619. Clin Rheumatol. 1984. PMID: 6432410 Clinical Trial.